Livraison suivie dans le monde entier | Env. 9–14 jours ouvrés

Votre panier

Votre panier est vide

Commencer à parcourir

Livraison gratuite pour les commandes de plus de €500.

Sous-total€0
Passer à la caisse
CognitifClinique

Oxytocin

Recherche publiée et base de preuves

Oxytocin is a nine-amino-acid neuropeptide synthesised in the hypothalamus, with intranasal administration used since the mid-2000s as a research tool for probing social cognition, threat processing and affiliative behaviour in humans. The field is unusually large and unusually contested: early small-sample findings of enhanced trust, emotion recognition and amygdala modulation have been followed by large registered trials and preregistered meta-analyses showing small, heterogeneous and frequently null effects. Current syntheses point to sex-dependent amygdala modulation, a thalamus-striatum-insula circuit as the most reproducible neural signature, and a small significant signal in schizophrenia spectrum disorders. Intranasal delivery to the brain, dose-response and the appropriate outcome measures all remain methodologically unresolved.

En bref
  • L'ocytocine est un neuropeptide de neuf acides aminés synthétisé dans l'hypothalamus.
  • Les études ont rapporté des effets faibles, hétérogènes et souvent nuls sur la cognition sociale.
  • L'administration intranasale au cerveau et la dose-réponse restent non résolues.

47 études · 21 depuis 2023 · plus récente 2026

Études citées
47
Publiées 2023+
21
Article le plus récent
2026
Dernière révision
oct. 2026

Thèmes récurrents dans la littérature

  • social cognition
  • intranasal administration
  • amygdala reactivity
  • autism spectrum disorder trials
  • trust and affiliation
  • publication bias and replication
  • dose-response and inverted-U
  • sex differences
  • stress and cortisol

Identifiants du composé

CAS
50-56-6
PubChem
439302

Identité chimique

Ce qu'est Oxytocin, chimiquement.

Formule moléculaire
C43H66N12O12S2
Masse moléculaire
1007.2 g/mol
Numéro CAS
50-56-6
PubChem CID
439302
Également écrit

Pitocin, Ocytocin

Ces chiffres proviennent de la fiche PubChem pour ce composé et décrivent la base libre. Le peptide lyophilisé est normalement fourni sous forme de sel d'acétate ou de trifluoroacétate et contient de l'eau résiduelle, donc la masse de poudre dans un flacon ne correspond pas à la quantité suggérée par la masse moléculaire ci-dessus. La pureté chromatographique sur un certificat d'analyse ne résout pas cette différence non plus — comment lire un certificat d'analyse explique pourquoi.

Les preuves

47 études publiées.

Classées par rigueur du protocole d'étude, puis par date. Chaque entrée renvoie à sa source pour que les résultats puissent être vérifiés dans l'article plutôt que pris sur parole.

  1. 01Revue systématique2026

    Does intranasal oxytocin reduce symptoms of mental disorders? A meta-analysis of clinical trials

    Bonnieux J, et al. · Neuroscience and Biobehavioral Reviews · meta-analysis of 42 double-blind randomised controlled trials, pooled N=1922

    The pooled treatment effect was small and non-significant with substantial heterogeneity (g = 0.17, 95% CI -0.05 to 0.38, I-squared 77.4%), falling to g = 0.05 with zero heterogeneity after removing two substance-use-disorder outliers. A small significant effect remained in schizophrenia spectrum disorders (g = 0.12, 95% CI 0.01 to 0.23).

  2. 02Revue systématique2026

    A systematic review and meta-analysis of oxytocin modulation of amygdala responses to emotional stimuli and implications for anxiolytic effects

    Guo X, Zhang L, Zhang Q, Kendrick KM, Yao S · Neuroscience and Biobehavioral Reviews · meta-analysis of 55 neuroimaging studies, 3337 participants

    Oxytocin's effect on amygdala activity was gender-dependent: inhibition in males and enhancement in females. Activation likelihood estimation showed reduced activity in the centromedial subregion and bidirectional effects in the basolateral subregion.

  3. 03Revue systématique2026

    Effects of exogenous oxytocin on human brain function are regulated by oxytocin gene expression: A meta-analysis of 20 years of oxytocin neuroimaging and transcriptomic analyses

    Wang J, et al. · Neuroscience and Biobehavioral Reviews · neuroimaging meta-analysis and transcriptomic analysis across 75 task-fMRI experiments, n=2247

    Consistent domain-general effects appeared in left thalamus, pallidum, caudate and insula, but not the amygdala. These regions formed an integrated thalamus-striatum-insula circuit enriched for CD38, OXT and OXTR expression.

  4. 04Revue systématique2026

    Using EEG to Measure the Neural Effects of Oxytocin Administration: A Meta-Analysis and Systematic Review

    Deilhaug E, et al. · Psychophysiology · systematic review and meta-analysis of EEG studies of oxytocin administration

    The review synthesised electrophysiological evidence for central effects of administered oxytocin, addressing whether EEG provides a more sensitive readout than behavioural endpoints.

  5. 05Revue systématique2026

    Intranasal oxytocin for alcohol use disorder: A systematic review and multilevel, bayesian, and variance meta-analyses of randomized clinical trial data

    Santos VH, et al. · Psychoneuroendocrinology · systematic review with multilevel, Bayesian and variance meta-analyses of randomised clinical trial data in alcohol use disorder

    The review pooled randomised trial evidence for intranasal oxytocin in alcohol use disorder using multiple synthesis frameworks, addressing the heterogeneity that had driven outlier effects in earlier pooled analyses.

  6. 06Revue systématique2025

    Effects of oxytocin administration on non-social executive functions in humans: a preregistered systematic review and meta-analysis

    Kang H, et al. · Molecular Psychiatry · preregistered meta-analysis of 20 effect estimates from 13 eligible studies (PROSPERO CRD42022308149)

    There was no overall significant effect on non-social executive function (Hedges' g = 0.07, p = 0.30). A significant effect emerged only for cognitive flexibility (g = 0.2, p = 0.02), with moderate Bayesian support for absence of publication bias.

  7. 07Revue systématique2025

    A multiverse meta-analysis of oxytocin administration studies

    Kang H, Deilhaug E, Walle KM, Sartorius AI, Quintana DS · Biological Psychology · 256 distinct meta-analyses across 530 effect sizes from 185 studies, systematically varying inclusion criteria, synthesis models and bias-correction methods

    Summary estimates ranged from d = -0.16 to d = 1.45 depending on analytic choices, yet over 90% of the specifications exceeded bootstrapped null distributions. Neurotypical samples and multiple-administration designs yielded larger effects.

  8. 08Revue systématique2025

    Dose-response effects of exogenous oxytocin on social cognition: A systematic review

    Barton S, Pruin A, Schulze J, Kiebs M, Scheele D, Hurlemann R · Neuroscience and Biobehavioral Reviews · systematic review of intranasal doses from 1 IU to 48 IU in healthy adults; emotion recognition, empathy and interpersonal trust

    Most studies used 24 IU and generally reported improved emotion recognition, empathy and trust, though divergent findings at the same dose occurred. Support for the inverted-U dose-response model came largely from studies lacking direct dose comparisons.

  9. 09Revue systématique2025

    Oxytocin in old age psychiatry: A systematic review of the safety of using intranasal oxytocin in older adults.

    Sawares A, et al. · Australas Psychiatry · systematic review of 9 RCTs, n=331 participants aged 60+

    Adverse effects of intranasal oxytocin in older adults were predominantly mild and inconsistent across studies, and oxytocin was not significantly associated with severe adverse outcomes after single or short-term repeated use; long-term safety was not assessed.

    Résultat de sécurité signalé. No serious adverse events were associated with short-term intranasal oxytocin in adults over 60; long-term safety remains untested.

  10. 10Revue systématique2024

    The effects of oxytocin administration on social and routinized behaviors in autism: A preregistered systematic review and meta-analysis

    Audunsdottir K, et al. · Psychoneuroendocrinology · preregistered frequentist and Bayesian meta-analysis of oxytocin administration trials in autism

    A small significant effect was found for social outcomes (d = 0.22, p < 0.001) but not routinised behaviours (d = 0.14, p = 0.22). Publication-bias assessments indicated the social effect size may be inflated.

  11. 11Revue systématique2023

    Endogenous oxytocin and human social interactions: A systematic review and meta-analysis

    Burenkova OV, et al. · Psychological Bulletin · 63 studies in qualitative synthesis, 51 pooled, n=3741 participants, publications 1970 to July 2020

    Social interaction did not produce the expected endogenous oxytocin response in causal designs (pre-post g = 0.079; between-condition g = 0.256), while correlational designs showed a small non-zero association (z = 0.137). The authors called for standardised measurement of oxytocin concentrations.

  12. 12Revue systématique2023

    Effects of intranasal oxytocin on pain perception among human subjects: A systematic literature review and meta-analysis.

    Lopes S, Osório FL · Horm Behav · systematic review and meta-analysis, 15 studies, clinical and experimental pain

    Intranasal oxytocin had no significant effect on pain intensity (SMD -0.02) or pain unpleasantness (SMD -0.15) compared with placebo.

  13. 13Revue systématique2018

    Systematic review and meta-analysis of reported adverse events of long-term intranasal oxytocin treatment for autism spectrum disorder.

    Cai Q, et al. · Psychiatry Clin Neurosci · systematic review and meta-analysis of 5 RCTs, n=223 (123 oxytocin, 100 placebo), autism

    Nasal discomfort, tiredness, irritability, diarrhoea and skin irritation were the most common adverse events, none statistically associated with oxytocin; five severe events occurred (aggression: 2 oxytocin, 1 placebo; seizures: 1 in each arm).

    Résultat de sécurité signalé. Common adverse events did not differ from placebo; severe events (aggression, seizures) were rare and occurred in both arms.

  14. 14Revue systématique2011

    A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research.

    MacDonald E, et al. · Psychoneuroendocrinology · systematic review of 38 RCTs (1990-2010), N=1529 participants, plus search for adverse-reaction reports

    Side effects did not differ between oxytocin and placebo, participants could not tell which they had received, and short-term research use was not associated with adverse outcomes; three case reports of adverse reactions involved misuse or longer-term use.

    Résultat de sécurité signalé. Short-term research use showed no reliable side effects versus placebo, with three adverse-reaction case reports linked to misuse or longer-term use.

  15. 15Clinique humaine2026

    Intranasal Oxytocin for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled Multisite Trial Assessing Efficacy and Safety

    Tiouririne NA, et al. · Alcohol, Clinical & Experimental Research · 12-week double-blind placebo-controlled multisite trial, n=100 with alcohol use disorder, up to 70 IU/day intranasal oxytocin

    No significant between-group difference was observed in percentage of heavy drinking days over the 10-week maintenance phase, and secondary drinking outcomes followed the same pattern. Participants on oxytocin scored significantly lower on anger and physical aggression at end of treatment, and tolerability was good.

  16. 16Clinique humaine2026

    Post-encoding administration of oxytocin selectively enhances memory consolidation of male faces in females

    Liu W, Li J, Chen Z, Zhao Q, Sun X · Proceedings of the National Academy of Sciences of the United States of America · three preregistered randomised double-blind placebo-controlled trials, total N=445 (227 male, 218 female), oxytocin given post-encoding, pre-retrieval or pre-encoding

    Post-encoding oxytocin, but not pre-retrieval or pre-encoding administration, improved female participants' recognition of male faces 24 h later, with no equivalent effect in males. The authors localised the effect to consolidation rather than encoding or retrieval.

  17. 17Clinique humaine2026

    Intranasal Oxytocin and Physical Intimacy for Dermatological Wound Healing and Neuroendocrine Stress: A Randomized Clinical Trial

    Schneider E, et al. · JAMA Psychiatry · double-blind randomised placebo-controlled trial, 80 heterosexual couples (N=160, mean age 27.6), 7 days twice-daily oxytocin or placebo with suction-blister wounds and 5-day ecological momentary assessment

    Couples receiving oxytocin alongside a structured partner appreciation task showed improved wound healing (b = -0.125, P = .048), though this was not robust in sensitivity analyses. Oxytocin combined with affectionate touch or sexual activity was associated with reduced wound severity, and greater sexual activity with lower daily cortisol.

  18. 18Clinique humaine2026

    Intravenous Oxytocin Has no Effect on Ad Libitum Food Intake or Postprandial Plasma Glucose Concentrations in Individuals With Obesity: A Randomised, Placebo-Controlled, Double-Blind, Crossover Study.

    Gether IM, et al. · Diabetes Obes Metab · randomised placebo-controlled double-blind crossover study, twenty-four adults with obesity (completers), 4.5-hour intravenous oxytocin versus saline infusion before an ad libitum meal

    Ad libitum food intake was similar with oxytocin and saline (714 vs 707 kcal). Oxytocin did not affect appetite sensations, plasma glucose, insulin, C-peptide, glucagon, GLP-1, GIP, cholecystokinin or gastric emptying.

  19. 19Clinique humaine2025

    Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trial

    Coleman KKL, et al. · The Lancet Neurology · adaptive crossover phase 2a/2b trial across 11 clinics in Canada and the USA, 94 participants, 72 IU intranasal oxytocin twice daily on varying schedules vs placebo

    Oxytocin every third day improved the Neuropsychiatric Inventory apathy score by an estimated -1.32 points relative to placebo (95% CI -2.43 to -0.21, one-sided p = 0.010) and was well tolerated, with no adverse events attributed to treatment.

  20. 20Clinique humaine2024

    The effect of intranasal oxytocin on neurocognition in people with schizophrenia: A randomized controlled trial

    İmamoğlu A, Stiles BJ, Jarskog LF, Pedersen CA, Elliott T, Penn DL · Journal of Psychiatric Research · 12-week randomised controlled trial, n=67 participants with schizophrenia or schizoaffective disorder, comprehensive neuropsychological battery at baseline and 12 weeks

    Intranasal oxytocin did not significantly improve cognition compared with placebo. The authors noted that timing of cognitive assessment relative to dosing was not standardised.

  21. 21Clinique humaine2024

    Effects of four-week intranasal oxytocin administration on large-scale brain networks in older adults

    Liu P, et al. · Neuropharmacology · randomised controlled trial of four-week intranasal oxytocin in older adults, resting-state network analysis

    Four weeks of intranasal oxytocin altered large-scale brain network organisation in older adults, one of the few chronic-dosing neuroimaging datasets in an ageing sample.

  22. 22Clinique humaine2024

    Intranasal Oxytocin for Obesity.

    Plessow F, et al. · NEJM Evid · RCT, n=61 adults with obesity, 8 weeks intranasal oxytocin vs placebo

    Body weight change did not differ from placebo (0.20 vs 0.26 kg), and there were no benefits on fat mass, visceral or liver fat or resting energy expenditure; caloric intake at a test meal was lower with oxytocin, and adverse events did not differ between groups.

  23. 23Clinique humaine2023

    The effect of oxytocin nasal spray on social interaction in young children with autism: a randomized clinical trial.

    Guastella AJ, et al. · Mol Psychiatry · double-blind randomised placebo-controlled trial after a 3-week placebo lead-in, n=87 children aged 3-12 years with autism, intranasal oxytocin for 12 weeks

    Oxytocin had no overall effect on caregiver-rated social responsiveness (SRS-2, p = 0.686), although an age interaction (p = 0.028) suggested some benefit in children aged 3-5 years. There was no benefit on clinician-rated global improvement or any secondary measure, and adverse effects were reported more often with placebo.

  24. 24Clinique humaine2021

    Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder

    Sikich L, et al. · The New England Journal of Medicine · 24-week placebo-controlled phase 2 trial, n=290 randomised (146 oxytocin, 144 placebo), ages 3-17, target 48 IU intranasal daily

    The least-squares mean change in ABC modified Social Withdrawal score was -3.7 with oxytocin and -3.5 with placebo (difference -0.2, 95% CI -1.5 to 1.0, P = 0.61). Secondary outcomes generally did not differ, making this the definitive negative trial in autism.

  25. 25Clinique humaine2021

    Continued versus discontinued oxytocin stimulation in the active phase of labour (CONDISOX): double blind randomised controlled trial.

    Boie S, et al. · BMJ · international multicentre double-blind randomised trial (CONDISOX), n=1200 women receiving intravenous oxytocin in induced labour, oxytocin discontinued versus continued in the active phase

    Caesarean rates were 16.6% with discontinuation and 14.2% with continuation (relative risk 1.17, 95% CI 0.90 to 1.53). Continued oxytocin shortened labour but was associated with more uterine hyperstimulation (12.9% vs 3.7%) and fetal heart rate abnormalities (40.8% vs 27.9%); other maternal and neonatal outcomes were similar.

    Résultat de sécurité signalé. Continued oxytocin infusion was associated with more uterine hyperstimulation and abnormal fetal heart rate patterns than discontinuation.

  26. 26Clinique humaine2021

    High-Dose Compared With Standard-Dose Oxytocin Regimens to Augment Labor in Nulliparous Women: A Randomized Controlled Trial.

    Son M, et al. · Obstet Gynecol · double-blind randomised trial, n=1003 nulliparous women at or beyond 36 weeks undergoing labour augmentation, high-dose versus standard-dose oxytocin regimens

    Caesarean birth occurred in 14.5% with the high-dose and 14.4% with the standard-dose regimen (relative risk 1.01, 95% CI 0.75-1.37). The high-dose regimen shortened labour (9.1 vs 10.5 hours) and lowered clinical chorioamnionitis (10.4% vs 15.6%), with no significant differences in other perinatal outcomes.

  27. 27Clinique humaine2021

    Combined Oxytocin and Cognitive Behavioral Social Skills Training for Social Function in People With Schizophrenia.

    Buchanan RW, et al. · J Clin Psychopharmacol · 24-week double-blind placebo-controlled randomised trial at 2 sites, n=62 adults with schizophrenia or schizoaffective disorder, intranasal oxytocin or placebo added to cognitive behavioural social skills training, 3-month follow-up

    There were no significant group differences in social functioning, positive or negative symptoms, defeatist beliefs or asocial beliefs. Interpretation was complicated by site differences in baseline severity and in improvement.

  28. 28Clinique humaine2021

    Intranasal oxytocin as a treatment for chronic pelvic pain: A randomized controlled feasibility study.

    Flynn MJ, et al. · Int J Gynaecol Obstet · randomised double-blind within-subject crossover feasibility trial, twenty-one women with chronic pelvic pain (12 with analysable data), 2-week courses of intranasal oxytocin and placebo

    Relative to placebo, oxytocin improved pain severity but not pain-related interference, an effect driven by four women with a minimal clinically significant improvement (none on placebo). Adherence was excellent and adverse effects did not differ between oxytocin and placebo.

  29. 29Clinique humaine2020

    A registered replication study on oxytocin and trust.

    Declerck CH, et al. · Nat Hum Behav · preregistered double-blind placebo-controlled replication (registered report), powered >95%

    Oxytocin had no effect on trusting behaviour in the trust game under the minimal-social-contact condition used in the original 2005 study; an exploratory post hoc signal in people low in dispositional trust required confirmation.

  30. 30Clinique humaine2020

    Effect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: a randomized clinical trial.

    Yamasue H, et al. · Mol Psychiatry · multicentre randomised double-blind placebo-controlled parallel-group trial in Japan, n=106 adults aged 18-48 with autism spectrum disorder, intranasal oxytocin for 6 weeks

    Oxytocin did not differ from placebo on the primary endpoint, ADOS reciprocity, because both groups improved (effect size -0.08, P = .69). Oxytocin reduced ADOS repetitive behaviour and increased gaze fixation on socially relevant regions compared with placebo; adverse event rates did not differ, although one participant had temporary gynaecomastia.

  31. 31Clinique humaine2020

    Pain-modulating effects of oxytocin in patients with chronic low back pain.

    Boll S, et al. · Neuropharmacology · exploratory randomised placebo-controlled crossover fMRI study, 22 men with chronic low back pain and 22 healthy controls, intranasal oxytocin

    During heat pain applied to the lower back, oxytocin versus placebo reduced pain intensity ratings and increased caudate (striatal) BOLD responses in patients relative to controls. Oxytocin had no effect on spontaneously experienced back pain.

  32. 32Clinique humaine2018

    Heat-Stable Carbetocin versus Oxytocin to Prevent Hemorrhage after Vaginal Birth.

    Widmer M, et al. · N Engl J Med · randomised double-blind non-inferiority trial at 23 sites in 10 countries (CHAMPION), n=29,645 women after vaginal birth, intramuscular heat-stable carbetocin versus intramuscular oxytocin; oxytocin was given to the comparator arm

    Blood loss of at least 500 ml or use of additional uterotonics occurred in 14.4% of the oxytocin group and 14.5% of the carbetocin group, meeting non-inferiority; blood loss of at least 1000 ml occurred in 1.45% versus 1.51%, where non-inferiority was not shown. Use of additional uterotonics, interventions to stop bleeding and adverse effects did not differ significantly.

  33. 33Clinique humaine2018

    Intramuscular versus intravenous oxytocin to prevent postpartum haemorrhage at vaginal delivery: randomised controlled trial.

    Adnan N, et al. · BMJ · double-blind placebo-controlled randomised trial, n=1075 women at term aiming for vaginal delivery, intravenous versus intramuscular oxytocin for the third stage of labour

    Postpartum haemorrhage (500 mL or more) was not significantly lower with intravenous oxytocin (18.8% vs 23.2%; adjusted odds ratio 0.75, 95% CI 0.55 to 1.03). Severe haemorrhage (4.6% vs 8.1%), blood transfusion (1.5% vs 4.4%) and high-dependency admission (1.7% vs 3.7%) were less frequent with the intravenous route, without more side effects (4.1% vs 5.2%).

  34. 34Clinique humaine2016

    The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial.

    Yatawara CJ, et al. · Mol Psychiatry · double-blind randomised placebo-controlled crossover trial, thirty-one young children with autism, intranasal oxytocin and placebo for 5 weeks each with a 4-week washout

    Compared with placebo, oxytocin significantly improved the primary outcome of caregiver-rated social responsiveness. The nasal spray was well tolerated, and the most common adverse events were thirst, urination and constipation.

  35. 35Clinique humaine2015

    A double-blind randomized controlled trial of oxytocin nasal spray and social cognition training for young people with early psychosis.

    Cacciotti-Saija C, et al. · Schizophr Bull · double-blind randomised placebo-controlled trial, n=52 people aged 16-35 with early psychosis, intranasal oxytocin or placebo for 6 weeks combined with group social cognition training, 3-month follow-up

    Oxytocin showed no benefit over placebo on any primary or secondary outcome, including the Reading the Mind in the Eyes Test, symptom scales and social functioning. An exploratory post hoc analysis linked greater nasal spray use with reduced negative symptoms in the oxytocin group only.

  36. 36Clinique humaine2015

    Oxytocin reduces caloric intake in men.

    Lawson EA, et al. · Obesity (Silver Spring) · randomised placebo-controlled crossover study, n=25 fasting healthy men, single-dose intranasal oxytocin before a test breakfast

    Oxytocin reduced caloric intake, preferentially fat intake, and raised cholecystokinin without changing appetite ratings or other appetite-regulating hormones. Resting energy expenditure was unchanged, while substrate use shifted from carbohydrate to fat and insulin sensitivity improved.

  37. 37Clinique humaine2010

    Treatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in women not exposed to oxytocin during labour: a double-blind, randomised, non-inferiority trial.

    Winikoff B, et al. · Lancet · double-blind randomised non-inferiority trial at four hospitals, n=978 women with primary postpartum haemorrhage after vaginal delivery who had not received prophylactic oxytocin, intravenous oxytocin versus sublingual misoprostol as treatment

    Active bleeding was controlled within 20 minutes in 96% of women given oxytocin versus 90% given misoprostol, and additional blood loss of 300 mL or more occurred in 17% versus 30%. Shivering (17% vs 47%) and fever (6% vs 44%) were less common with oxytocin; no women had hysterectomies or died.

  38. 38Clinique humaine2010

    Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients.

    Feifel D, et al. · Biol Psychiatry · randomised double-blind placebo-controlled crossover trial, nineteen people with schizophrenia and residual symptoms on stable antipsychotics (15 completed), adjunctive intranasal oxytocin for 3 weeks

    Oxytocin significantly reduced Positive and Negative Syndrome Scale and Clinical Global Impression-Improvement scores versus placebo at the 3-week end point (p < .001), with no benefit at earlier time points. It was well tolerated, with no adverse effects on patient report or laboratory tests.

  39. 39Clinique humaine2008

    Oxytocin increases gaze to the eye region of human faces.

    Guastella AJ, et al. · Biol Psychiatry · double-blind randomised placebo-controlled between-subject eye-tracking study, n=52 healthy men, single intranasal dose

    Men given oxytocin made more fixations and spent more total gaze time on the eye region of neutral faces than men given placebo.

  40. 40Clinique humaine2007

    Oxytocin improves "mind-reading" in humans

    Domes G, Heinrichs M, Michel A, Berger C, Herpertz SC · Biological Psychiatry · randomised double-blind placebo-controlled crossover, healthy male volunteers, Reading the Mind in the Eyes Test

    Intranasal oxytocin improved performance on the Reading the Mind in the Eyes Test relative to placebo, particularly for difficult items. This established the emotion-recognition paradigm used throughout the subsequent literature.

  41. 41Clinique humaine2005

    Oxytocin increases trust in humans

    Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E · Nature · placebo-controlled trust game experiment in healthy male volunteers

    Intranasal oxytocin increased investors' transfers in a trust game relative to placebo without altering behaviour in a matched risk task. This is the foundational human study of the field; subsequent large replication attempts have not consistently reproduced the effect.

  42. 42Clinique humaine2005

    Oxytocin modulates neural circuitry for social cognition and fear in humans.

    Kirsch P, et al. · J Neurosci · double-blind placebo-controlled crossover fMRI study, n=15 healthy men, intranasal oxytocin

    Compared with placebo, oxytocin reduced amygdala activation to fear-inducing visual stimuli and reduced coupling of the amygdala to brainstem regions involved in autonomic and behavioural fear responses.

  43. 43Clinique humaine2003

    Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders.

    Hollander E, et al. · Neuropsychopharmacology · randomised double-blind placebo-controlled infusion challenge, n=15 adults with autism or Asperger's disorder, intravenous oxytocin

    Repetitive behaviours (need to know, repeating, ordering, need to tell or ask, self-injury and touching) were significantly reduced after oxytocin infusion compared with placebo infusion.

  44. 44Clinique humaine2001

    WHO multicentre randomised trial of misoprostol in the management of the third stage of labour.

    Gülmezoglu AM, et al. · Lancet · WHO multicentre double-blind randomised trial in hospitals across several countries, women delivering vaginally, intravenous or intramuscular oxytocin (n=9266) versus oral misoprostol (n=9264) in active management of the third stage of labour

    Measured blood loss of 1000 mL or more occurred in 3% of women given oxytocin versus 4% given misoprostol (relative risk for misoprostol 1.39, 95% CI 1.19-1.63), and additional uterotonics were needed by 11% versus 15%. Shivering and raised body temperature were more common with misoprostol, and the authors judged oxytocin preferable in hospital settings.

  45. 45Clinique humaine1996

    Induction of labor compared with expectant management for prelabor rupture of the membranes at term. TERMPROM Study Group.

    Hannah ME, et al. · N Engl J Med · multicentre randomised trial (TERMPROM), n=5041 women with prelabour rupture of membranes at term: induction with intravenous oxytocin, induction with vaginal prostaglandin E2, or expectant management with oxytocin or prostaglandin if needed

    Neonatal infection and caesarean rates did not differ significantly among groups (neonatal infection 2.0% after oxytocin induction; caesarean 9.6 to 10.9 percent). Oxytocin induction lowered clinical chorioamnionitis (4.0% vs 8.6%, P<0.001) and postpartum fever (1.9% vs 3.6%) compared with expectant management, and women rated induction more positively.

  46. 46Revue2021

    Advances in the field of intranasal oxytocin research: lessons learned and future directions for clinical research

    Quintana DS, et al. · Molecular Psychiatry · methodological review of intranasal oxytocin trial design

    The review catalogued dose selection, delivery device, timing, sex and context as major sources of heterogeneity, and set out design recommendations that later preregistered meta-analyses adopted.

  47. 47Revue2016

    Intranasal Oxytocin: Myths and Delusions

    Leng G, Ludwig M · Biological Psychiatry · critical quantitative review of intranasal delivery pharmacology

    The authors argued that the quantity of oxytocin reaching central receptors after intranasal dosing is very small relative to endogenous release, and that many reported behavioural effects are underpowered and statistically fragile.

Limites

Ce que ces preuves n'établissent pas.

The proportion of an intranasal dose that reaches central oxytocin receptors has never been directly quantified in humans, and no validated peripheral biomarker of central engagement exists. The largest randomised trial in autism was fully null, effect sizes across domains are small and highly sensitive to analytic choices, dose-response is not established from direct within-study dose comparisons, and effects appear to differ by sex and context in ways not yet predictable at the individual level. There is no approved indication for cognitive or social enhancement.

Questions courantes sur la recherche.

What is oxytocin?

Oxytocin is an endogenous nonapeptide produced in the hypothalamus, with an identified receptor in peripheral tissue and central projections to limbic and brainstem regions. In research it is best known from social-neuroscience studies using intranasal administration in healthy volunteers.

How settled are the social-behaviour findings?

Not very. The early trust and emotion-recognition results are widely cited but have attracted sustained methodological criticism over sample size, replication, and how much intranasally applied peptide reaches the brain. Current review guidance treats the field as unresolved and calls for pre-registered, larger-sample designs.

What did the largest randomised trial of intranasal oxytocin in autism find?

It was null. The 24-week placebo-controlled phase 2 trial randomised 290 participants aged 3 to 17 to intranasal oxytocin or placebo at a target of 48 IU daily. The least-squares mean change in the ABC modified Social Withdrawal score was -3.7 with oxytocin and -3.5 with placebo, a difference of -0.2 (95 percent CI -1.5 to 1.0, P = 0.61), and secondary outcomes generally did not separate. A 2024 preregistered meta-analysis found a small significant pooled effect on social outcomes (d = 0.22) that publication-bias assessment suggested may be inflated.

Disponible dans notre catalogue

À des fins de recherche uniquement. Non destiné à la consommation humaine, au diagnostic, au traitement ou à la prévention de toute condition. Rien sur cette page ne constitue un avis médical, et aucune étude résumée ici ne doit être considérée comme une recommandation.